Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 28, 2020 09:35 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Publishes Positive IBS-D Phase 2 Study Data in The American Journal of Gastroenterology

Publication of the Phase 2 U.S. study data show that RHB-102 (Bekinda®) 12mg delivers a clinically meaningful improvement in overall stool consistency response versus placebo in patients with...
September 12, 2018 07:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Announces Positive End-of-Phase II Meeting with FDA on BEKINDA® for IBS-D

The positive Type B meeting with the FDA followed a successful Phase II study of BEKINDA® for diarrhea-predominant irritable bowel syndrome (IBS-D), one of the most common gastrointestinal disorders ...
March 02, 2015 07:00 ET | Source: RedHill Biopharma Ltd.

Positive Bioavailability Studies of RedHill's BEKINDA(TM) to be Presented at the 2015 American Society for Clinical Pharmacology and Therapeutics (ASCPT) Meeting

The results from two positive bioavailability studies, previously reported by the Company, demonstrate the safety and tolerability of BEKINDA™ and support the European marketing application...
February 13, 2015 10:18 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Announces Closing of Public Offering of Its American Depository Shares

TEL-AVIV, Israel, Feb. 13, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on late...